SOURCE: SciClone Pharmaceuticals, Inc.

June 09, 2005 16:02 ET

SciClone Comments on Recent Trading Activity

SAN MATEO, CA -- (MARKET WIRE) -- June 9, 2005 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today commented that the current market activity in its stock could be the result of an article reporting that Sonae SGPS, SA, a Portuguese company, is preparing to make a tender offer for SciClone. SciClone had not been contacted by Sonae and had no reason to believe that a tender offer was likely. While the company's policy is not to respond to rumors or speculative activity, SciClone believes that the nature of the rumor and its potential effect on its stock trading made it important to advise its stockholders that the company has no basis to confirm or deny Sonae's intent and is not aware of any substance behind this speculation. SciClone undertakes no obligation to comment further on the subject of this press release.

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN® is currently being evaluated in two phase 3 hepatitis C clinical trials in the United States. ZADAXIN is also being evaluated in other late-stage clinical trials for the treatment of hepatitis B and certain cancers. The company's other principal drug development candidate is SCV-07, which is currently being evaluated in pre-clinical studies for the treatment of viral and other infectious diseases. For more information about SciClone, visit www.sciclone.com.

Contact Information

  • Corporate contact:
    Becky Horner
    Investor Relations
    SciClone Pharmaceuticals, Inc.
    650-358-3437